RSV Vaccine Shortage Raises Concerns Among Pediatricians

Pediatricians warn of significant vaccine shortages for the RSV virus, potentially impacting infant health and straining hospitals.

The Berufsverband der Kinder- und Jugendärzte (BVKJ) criticizes both the government and insurance companies for not ensuring timely RSV vaccinations for infants.
High demand and manufacturing delays have led to long waiting lists for the Nirsevimab (Beyfortus) antibody, recommended for newborns and infants.
Sanofi, the vaccine manufacturer, is attempting to meet demand by sourcing doses from France, Spain, and the USA.
Pediatricians predict overwhelmed children's hospitals this winter due to RSV and existing structural healthcare issues.
Concerns are growing about the impact of hospital reforms, which could reduce the number of pediatric beds available.